Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Nanobiotix to present at immuno-oncology gathering this month

The company currently has seven clinical trials underway
picture of xray machine
Nanobiotix wants to trial its nano-xray therapy in a combination

Nanobiotix SA (EPN:NANO) has been invited to give two presentations to the Society for Immunotherapy of Cancer (SITC) conference this month for its flagship NBTXR3 treatment.

A pioneering approach to cancer, nanoparticles are injected directly into solid tumours to amplify the effects of shrinking treatment.

It has already demonstrated success tackling soft tissue sarcoma, a cancer that affects muscle, fat and blood vessels.

The company currently has seven clinical trials underway but is also exploring NBTXR3’s potential in immuno-oncology in combination therapies.

An investigational new drug application is being prepared for a combination trial in the US with checkpoint inhibitors, another of promising research in cancer treatment.

In January, meanwhile, first results from a phase I/II trial in liver cancer patients are expected and will be presented to the ASCO GI conference.

View full NANO profile View Profile

Nanobiotix SA Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use